VF5.F ONDINE BIOMEDICAL INC.CDI

Healthcare Biotechnology Frankfurt Exchange
0.0830 EUR
Close of Nov 12, 2026
0.0650 0.1950
Market cap
EUR 54.9M
P/E
-
P/B
20.67x
ROE
-847.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is VF5.F undervalued?

Graham number

The Graham number of ONDINE BIOMEDICAL INC.CDI cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONDINE BIOMEDICAL INC.CDI fundamental analysis

No fundamental analysis for ONDINE BIOMEDICAL INC.CDI yet.

ONDINE BIOMEDICAL INC.CDI stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONDINE BIOMEDICAL INC.CDI

Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-ass…

Full company profile